bluuebunny/crossref_metadata_2025 huggingface dataset:
A86 COST-EFFECTIVE ANALYSIS OF PRELIMINARY SINGLE-OPERATOR CHOLANGIOSCOPY IN MANAGEMENT OF DIFFICULT STONES
Authors: Sljivic I , Trasolini R , Donnellan F
Published: February 2022

Background

Single-operator peroral cholangioscopy (POC) is a therapeutic modality for difficult biliary stone disease. Given its high success rate and increasing availability, analysis of the economic impact of early POC utilization is critical for clinical decision-making.

Aims

We aim to compare the cost-effectiveness of different first and second-line endoscopic modalities for difficult-to-treat choledocholithiasis.

Methods

A decision tree model with a 1-year time horizon and a hypothetical cohort of 200 patients was used to analyze the cost-effectiveness of POC for first, second and third-line intervention in presumed difficult biliary stones. We adopted the perspective of a Canadian tertiary hospital, omitting complications and recurrence rates associated with ERCP. Effectiveness estimates were obtained from updated meta-analyses. One-way sensitivity analyses and probabilistic sensitivity analyses were also performed to assess how changes in key parameters affected model conclusions.

Results

First and second-line POC achieved comparable clinical efficacy from 95.5% to 96.5% stone clearance. The least expensive strategy is third-line POC (POC-3: $769,151). Performing POC during the second ERCP was marginally more expensive (POC-2: $770,832) but 9% more effective. The strategy of first-line POC incurred the highest hospital expenditures (POC-1: $848,141) but decreased total procedures performed by 13.4% when compared with POC-2. Sensitivity analysis was robust in showing POC-2 as the most optimal approach.

Conclusions

Second-line POC was superior to first and third-line POC for treatment of difficult biliary stones. When based on meta-analysis of non-heterogeneous trials, POC-2 is more cost-effective and cost-efficient. Our study warrants a larger pragmatic effectiveness trial.

Funding Agencies

None
A100 A PROVINCIAL APPROACH TO ASSESSING ENDOSCOPY PATIENT EXPERIENCE ENHANCES SITE PARTICIPATION AND CANADA-GLOBAL RATING SCALE COMPLIANCE
Authors: Oilund C , Morrin L , Moysey B , Jelinski S , Snider J , Underwood F , Spankie C , Nemecek N , Greenaway M
Published: February 2022

Background

The Canada-Global Rating Scale (C-GRS) is a web-based, patient centered endoscopy quality improvement tool. It assesses the quality of services a unit provides in two dimensions: clinical quality and patient experience. Endoscopy units submit results to the Canadian Association of Gastroenterology twice a year. In Alberta, units receive an A, B, C or D grade for each of the 12 C-GRS Items and a C-GRS score.

The C-GRS promotes that patient feedback is sought annually. Patient feedback is important because it informs practice improvement opportunities. However, survey creation, distribution, analysis and reporting can be time consuming and costly for an endoscopy unit and is a potential barrier to participation.

Aims

The purpose of this quality improvement project is to demonstrate how a provincial infrastructure, which includes coordination, management and reporting of an endoscopy patient satisfaction survey, can enhance provincial endoscopy unit survey participation and facilitate C-GRS compliance.

Methods

The Digestive Health Strategic Clinical Network (DHSCN), the Alberta Colorectal Cancer Screening Program and Primary Data Support (PDS) collaborated on the Provincial Endoscopy Patient Experience Survey (PEPES) in 2019. An existing paper survey was adapted to meet the needs of the 50 endoscopy units in AB with the addition of an electronic version. Education about the PEPES process was provided via a webinar and site visits. Each unit was responsible for distribution of the surveys to their patients. PDS coordinated the paper survey process and the DHSCN managed the electronic survey submissions. Paper survey results were merged with electronic PEPES data. A summary report was provided to units and shared with each AHS Zone Endoscopy Executive Leadership Team.

Results

Provincially coordinated implementation of the PEPES fosters compliance with C-GRS criteria. Participating endoscopy units were able to achieve at minimum 9 C-GRS descriptors and improve their C-GRS score in the following 7 of the 12 C-GRS Items: consent, comfort, equality, booking, privacy, aftercare and feedback.

Initial enrollment in the PEPES increased with the onset of provincial coordination (Figure 1). However, subsequent participation was negatively impacted by COVID-19 as many endoscopy units in AB were required to decrease their capacity and redeploy staff.

Conclusions

A provincially coordinated approach to the management of an endoscopy patient experience survey is an effective way to enhance site participation and improve C-GRS scores. Units can focus on actioning survey results, rather than the burden of survey administration. Future work includes comparison of results across sites allowing for potential provincial equity issues to be addressed.

Funding Agencies

None
A108 A RETROSPECTIVE REVIEW OF COMPLEX POLYP MANAGEMENT IN THE CHAMPLAIN REGION, ONTARIO
Authors: Monod A , Rostom A , Dube C
Published: February 2022

Background

Advanced endoscopic techniques have enabled the removal of polyps which, due to their size, location, or morphology, would otherwise have been removed surgically. Patients with such complex polyps should be referred promptly to expert centres for adjudication and management.

Aims

To review patterns of referral and initial management of complex polyps at The Ottawa Hospital (TOH), to identify gaps in care and to identify strategies to address those gaps.

Methods

We performed a retrospective chart review of cases where large (>3cm) colonic polyps were evaluated at TOH, from March 2019-March 2021. Cases were identified using Canadian Institute of Health Information codes. Descriptive statistics were analyzed, and were compared using Mann-Whitney U tests where appropriate.

Results

94 consecutive patients with large polyps (mean age 68; 56.4% male) were included. The average polyp size was 4.7(4.4–5.1)cm. 45 patients were referred for a known complex polyp while the rest were referred for FIT/FOBT+ (n=20), symptoms or anemia (n=17), surveillance (n=9), or abnormal imaging (n=3). 32 patients were referred from >50km from Ottawa (travelling), and 62 were referred from <50km from Ottawa (local). Of the 45 referrals for known polyp, 20 (44.4%) included photodocumentation of the lesion; 33 (73.3%) had a prior biopsy, and 8 (17.8%) were partially removed. Key statistics are summarized in Table 1. All 8 patients referred with a partially removed polyp eventually had a successful endoscopic polypectomy. 10/94 (10.6%) patients required surgical resection: 7 for malignant pathology, and 3 for endoscopic failure. Overall, 3 patients had post-polypectomy bleeding, and 1 patient sustained a full-thickness perforation. As of October 2021, 26/78 (33.3%) patients eligible for a 4–6 month recheck and 36/48 (75%) patients eligible for a 12-month follow-up colonoscopy were overdue.

Conclusions

This retrospective review highlights significant differences in the management of complex polyps based on patient geography and the need to develop strategies to improve access for patients referred from outside of Ottawa. As expected, COVID had a significant impact on the time to complete removal of polyps, and affected the timely endoscopic follow up of these high-risk patients. Strategies to ensure timely endoscopic follow up of patients after complex polyp removal are needed.

Funding Agencies

None
A109 PATIENTS’ DESCRIPTIONS OF THEIR LAST BOWEL MOVEMENT BEFORE COLONOSCOPY CORRELATES STRONGLY WITH THEIR BOSTON BOWEL PREPARATION SCALE (BBPS) SCORE WHEN ASSESSED USING A STANDARDIZED METHOD
Authors: Akman O , Gregor J C , Singh H
Published: February 2022

Background

Predicting bowel prep quality prior to colonoscopy may help improve colonoscopy prep quality by instituting adjunct measures before colonoscopy. This will in turn reduce repeat procedures, complications, and costs.

Aims

We determined the utility of a standardized method to obtain information from patients on the characteristics of their last bowel movement before colonoscopy by correlating the obtained information to BBPS. We compared this approach to informal/usual descriptions attained by nurses.

Methods

This is a cross-sectional study with data collected at two tertiary care hospitals. On the day of their colonoscopy, outpatients were asked by an assistant to describe their last bowel movement using a standardized method. The same patients had previously been asked by endoscopy nurses to describe their last bowel movement; the assistant was blind to previous descriptions. Descriptions were assigned a score (Table 1).

Following colonoscopy, total and segmental BBPS scores were recorded by the gastroenterologist performing the procedure; the gastroenterologist was blind to the descriptions.

Bivariate Pearson’s Correlation was used to separately assess the correlation between descriptions and BBPS. Cohen’s Kappa was used to assess agreement between the two descriptions.

Results

121 patients (ages 17–86; 55% Female) with 11% BBPS< 6 were included.

For descriptions attained by the assistant, there was a strong correlation with total BBPS score (r = 0.738; p < 0.001); correlation to segmental BBPS was moderate-to-strong (r=0.70, 0.63 and 0.67 right, transverse and left colon respectively).

For descriptions attained by endoscopy nurses, there was a moderate correlation with total BBPS score (r = 0.525; p < 0.001); correlation to segmental BBPS was weak-to-moderate (r=0.52, 0.49 and 0.44 right, transverse and left colon respectively).

There was weak agreement (K = 0.525) between description attained by assistant and nurses.

Conclusions

When asked using a standardized method, a patient’s description of their last bowel movement correlates strongly with their total and segmental BBPS score; the correlation is weaker for non-standardized descriptions attained by endoscopy nurses. A standardized questionnaire, including assessing consistency, is valuable in assessing the bowel movement before colonoscopy.

Funding Agencies

None
A111 A RECTUM-SPECIFIC SELECTIVE RESECTION ALGORITHM OPTIMIZES ONCOLOGIC OUTCOMES FOR LARGE NON-PEDUNCULATED RECTAL POLYPS
Authors: Shahidi N C , Vosko S , Gupta S , Whitfield A , Cronin O , O’Sullivan T , van Hattem W , Sidhu M , Tate D , Lee E , Burgess N , Williams S , Bourke M
Published: February 2022

Background

Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are complementary techniques for large (≥ 20mm) non-pedunculated rectal polyps (LNPRPs). A mechanism for appropriate technique selection has not been described.

Aims

To evaluate whether a selective resection algorithm using EMR and ESD, based on real-time optical evaluation, optimizes oncologic outcomes for LNPRPs

Methods

We evaluated the performance of a selective resection algorithm (SRA; 08/2017-04/2021) compared to a universal EMR algorithm (UEA; 07/2008-07/2017) for LNPRPs within a prospective observational study. In the SRA, LNPRPs with features of superficial submucosal invasive cancer (SMIC < 1000μm; S-SMIC; Kudo pit pattern Vi), or with an increased risk of SMIC (Paris 0-Is or 0-IIa+Is non-granular, 0-IIa+Is granular with a dominant nodule ≥ 10mm) underwent ESD. The remaining LNPRPs underwent EMR. Algorithm performance was evaluated by SMIC identified after EMR, curative oncologic resection (R0 resection, S-SMIC, absence of negative histologic features), technical success, adverse events, and recurrence at first surveillance colonoscopy.

Results

480 LNPRPs were evaluated (290 UEA, 190 SRA). Median lesion size was 40mm (IQR 30-60mm). In the SRA, 103 (54.2%) and 87 (45.8%) LNPRPs underwent EMR and ESD, respectively. SMIC was identified in 56 (11.7%) LNPRPs. Significant differences in SMIC after EMR (SRA 1 (1.0%) vs. UEA 35 (12.1%); p = 0.001), curative oncologic resection (SRA 7 (33.3%) vs. UEA 2 (5.7%); p = 0.010), and recurrence (SRA 2 (1.6%) vs. UEA 40 (17.2%); p < 0.001) were identified. No significant differences in technical success or adverse events were identified (all p > 0.137). Among potentially curable malignant LNPRPs which underwent ESD, 100% (7/7) were cured.

Conclusions

A SRA optimizes oncologic outcomes for LNPRPs and mitigates the risk of piecemeal resection of cancers.

Funding Agencies

The Cancer Institute of New South Wales provided funding for a research nurse and data manager to assist with the administration of the study. Neal Shahidi was supported by the University of British Columbia Clinician Investigator Program. There was no influence from either institution regarding study design or conduct, data collection, management, analysis, interpretation, preparation, review, or approval of the manuscript.
A118 UPPER GASTROINTESTINAL HEMORRHAGE SECONDARY TO SUPERIOR MESENTERIC ARTERY PSEUDOANEURYSM: CASE REPORT AND REVIEW OF LITERATURE
Authors: Guo H , Stach J , Panaccione R , Belletrutti P J
Published: February 2022

Background

Visceral artery pseudoaneurysms (VAPAs) are rare with an estimated incidence of 0.1%-0.2%. Due to various etiologies, a tear occurs in the vessel wall with subsequent formation of a peri-artery hematoma. A ruptured VAPA is a clinical emergency due to life-threatening hemorrhage and is associated with mortality rates of 25%-75%.

Aims

We report a case of upper gastrointestinal (GI) hemorrhage secondary to a ruptured superior mesenteric artery (SMA) pseudoaneurysm. A review of the literature regarding management of VAPAs and SMA pseudoaneurysms was performed using relevant medical subject headings on PubMed.

Methods

A 66-year-old woman presented to hospital with sudden large volume hematemesis and melena. Her daily medications included Aspirin and Atorvastatin. She had no prior history of peptic ulcers or chronic liver disease. She was found to be tachycardic and hypotensive. Initial investigations demonstrated a hemoglobin of 42g/L and a blood urea nitrogen of 17.5mmol/L. She was resuscitated and referred for an emergent upper endoscopy. On endoscopy, in the third portion of the duodenum, a 4cm solid-appearing subepithelial lesion with central umbilication and an apparent visible vessel was identified. Upon inspection of the lesion, the umbilicated area spontaneously began spurting blood (Image 1). A hemoclip was immediately placed next to the lesion for localization, then hemostatic powder was applied to the area. An immediate computerized tomography (CT) angiography of the abdomen revealed a 3.9 x 2.1 cm pseudoaneurysm arising from the superior mesenteric artery impressing upon the duodenum.

Results

Transcathether arterial embolization of the SMA pseudoaneurysm was performed, during which two Nester coils were deposited in the ileocolic outflow vessel. A covered endovascular stent was also deployed across the culprit arterial branch to exclude the pseudoaneurysm. Following the procedure, the patient stabilized and had no further GI bleeding. Traditionally, visceral angiography has been the gold standard diagnostic test for VAPAs, but has now been supplanted by CT angiography. Treatment strategies of VAPAs can be broadly separated into endovascular methods (coils, vascular plugs, stents, liquid embolic agents) and surgical methods (aneurysmectomy with patching, end-to-end anastomosis, bypass grafting).

Conclusions

SMA pseudoaneurysms are a rare yet life-threatening cause of GI bleeding. Endoscopically, they resemble solid subepithelial masses, such as GI stromal tumor, nerve sheath tumor or a lipoma, which may lead to inappropriate attempts to biopsy the lesion or apply direct endoscopic therapy. Prompt diagnosis with imaging, such as CT angiography, is paramount with a view to definitive treatment of the pseudoaneurysm via endovascular methods.

Actively hemorrhagic SMA pseudoaneurysm

Funding Agencies

None
A121 QUANTIFYING INTER-OBSERVER VARIABILITY IN THE SEGMENTATION OF RECTAL TUMORS IN ENDOSCOPY IMAGES AND ITS EFFECTS ON DEEP LEARNING
Authors: Weishaupt L L , Vuong T , Thibodeau-Antonacci A , Garant A , Singh K S , Miller C , Martin A , Enger S
Published: February 2022

Background

Tumor delineation in endoscopy images is a crucial part of clinical diagnoses and treatment planning for rectal cancer patients. However, it is challenging to detect and adequately determine the size of tumors in these images, especially for inexperienced clinicians. This motivates the need for a standardized, automated segmentation method. While deep learning has proven to be a powerful tool for medical image segmentation, it requires a large quantity of high-quality annotated training data. Since the annotation of endoscopy images is prone to high inter-observer variability, creating a robust unbiased deep learning model for this task is challenging.

Aims

To quantify the inter-observer variability in the manual segmentation of tumors in endoscopy images of rectal cancer patients and investigate an automated approach using deep learning.

Methods

Three gastrointestinal physicians and radiation oncologists (G1, G2, and G3) segmented 2833 endoscopy images into tumor and non-tumor regions. The whole image classifications and the pixelwise classifications into tumor and non-tumor were compared to quantify the inter-observer variability. Each manual annotator is from a different institution.

Three different deep learning architectures (FCN32, U-Net, and SegNet) were trained on the binary contours created by G2. This naive approach investigates the effectiveness of neglecting any information about the uncertainty associated with the task of tumor delineation.

Finally, segmentations from G2 and the deep learning models’ predictions were compared against ground truth labels from G1 and G3, and accuracy, sensitivity, specificity, precision, and F1 scores were computed for images where both segmentations contained tumors.

Results

The deep-learning segmentation took less than 1 second, while manual segmentation took approximately 10 seconds per image. There was significant inter-observer variability for the whole-image classifications made by the manual annotators (Figure 1A). The segmentation scores achieved by the deep learning models (SegNet F1:0.80±0.08) were comparable to the inter-observer variability for the pixel-wise image classification (Figure 1B).

Conclusions

The large inter-observer variability observed in this study indicates a need for an automated segmentation tool for tumors in endoscopy images of rectal cancer patients. While deep learning models trained on a single observer’s labels can segment tumors with an accuracy similar to the inter-observer variability, these models do not accurately reflect the intrinsic uncertainty associated with tumor delineation. In our ongoing studies, we investigate training a model with all observers’ contours to reflect the uncertainty associated with the tumor segmentations.

Funding Agencies

CIHRNSERC
A124 INITIAL EXPERIENCES AND OUTCOMES IN LAUNCHING AN ESD PROGRAM IN CANADA
Authors: Jeyalingam T , Forbes N , Heitman S , Belletrutti P J
Published: February 2022

Background

Endoscopic submucosal dissection (ESD) is emerging as the preferred modality for curative resection of certain gastrointestinal lesions, yet it has a steep learning curve. Formal ESD training in Canada is limited, thus several endoscopists have sought training abroad. There are no data on the initial outcomes of ESD in Canada.

Aims

To describe the experience of a single advanced endoscopist (P.B.) who completed a mentor-apprentice model of ESD training in Europe and recently launched an ESD service in Canada.

Methods

Formal training in submucosal endoscopy was completed over a 12-month period (Sep 2018-Aug 2019) in Milan, Italy involving a stepwise progression through case observation (n=40), use of animal models (n=10), partial completion of human cases under direct supervision (n=25), and independent completion of human cases (n=19). Upon return to Calgary, AB, the program was promoted via grand rounds, an evening launch event and word-of-mouth. Patient and lesion characteristics, as well as procedure details and ESD outcomes were recorded prospectively in a database and used to complete a practice audit. Cases were divided into two timeframes (first 18 vs second 18 cases) and then compared with respect to specimen size, resection speed, R0 resection rate, and adverse event (AE) rate using the Mann-Whitney U and two-proportion Z-tests.

Results

From Nov 2019 to Sep 2021, 36 lesions were treated by ESD in 34 patients (mean (SD) age=66.5 (13.5) years). Most lesions were located in the rectum (44.4%) or stomach (41.7%); 21 (58.3%) were neoplastic, of which 5 (23.8%) were submucosal carcinomas, 11 (52.3%) were mucosal carcinomas (7 m1/Tis, 4 m2-3/T1a), and 5 (23.8%) were neuroendocrine tumors. The overall en bloc resection rate was 97.2% (35/36 lesions). In comparing the first 18 cases to the second 18 cases (Table 1), there were non-significant trends toward increases in mean specimen size (5.4 to 8.6 cm2, P=0.07) and R0 resection rate (62.5% to 84.6%, P=0.24). Resection speed increased significantly (2.97 to 6.25 cm2/hr, P=0.04), while AE rates remained the same (11.1%); namely 2 episodes of bleeding requiring repeat endoscopy in each set of cases. There were no perforations or intra-abdominal infections.

Conclusions

With appropriate training and support, ESD can be performed safely and effectively in a Canadian context. Proficiency can be expected to improve significantly within the first 2 years of independent ESD practice without compromising safety.

Funding Agencies

None
A135 DO VISCOUS SWALLOWS IMPROVE THE DIAGNOSTIC YIELD OF HIGH-RESOLUTION MANOMETRY?
Authors: Ricci M , Rodrigues D , Reed D E
Published: February 2022

Background

Esophageal motility disorders are diagnosed using high-resolution esophageal manometry (HR-EMS) using the Chicago Classification (CC V4.0) which is based on a series of 10 normal saline swallows (LS). Viscous swallows (VS; thickened liquid/applesauce) are often performed during esophageal manometry; however, they were not included within the framework of CC V4.0. Previous literature has suggested inconsistency between LS and VS in up to 25% of studies, yet it remains unclear whether routine use of VS offers any benefit to LS alone in diagnosing manometric abnormalities according to the CC V4.0.

Aims

To determine if the routine use of VS improves the diagnostic yield in HR-EMS

Methods

A retrospective analysis of all HR-EMS studies performed between December 2020 and July 2021 at Kingston Health Sciences Centre was completed. Demographic information including age, sex, indication for HR-EMS, surgical history, and chronic narcotic use was documented. Each study (consisting of 10 LS and 10 VS) was reviewed independently by a Gastroenterology Fellow and Neurogastroenterologist. A manometric diagnosis using CC V4.0 was made for both LS and VS. Descriptive statistics were performed.

Results

A total of 101 HR-EMS studies were reviewed (33 male, 68 female, age range 26 to 90 years). The most common indication for HR-EMS was dysphagia (87/101) with 23/101 having 2 indications, 30/101 having 3 indications, and 43/101 patients having >3 indications. Prior upper GI tract surgery and chronic narcotic use was recorded in 9/101 and 8/101 patients, respectively. Two HR-EMS studies were excluded due to incomplete protocol. In total, 38.4% (38/99) had normal HR-EMS for both LS and VS. LS and VS that resulted in a CC V4.0 diagnosis were concordant in 37.4%(37/99) and discordant in 24.2% (24/99). Of the 24 discordant studies, 6 had a CC V4.0 diagnosis for LS (4 esophagogastric outflow obstruction (EGJOO), 1 ineffective esophageal motility (IEM), 1 diffuse esophageal spasm) and normal VS. Ten studies had normal LS and a CC V4.0 diagnosis for VS (9 IEM, 1 EGJOO). Eight had differing CC V4.0 diagnoses for LS and VS.

Conclusions

LS and VS resulted in concordant diagnoses in the majority of cases. However, there were discordant results in approximately 25% of cases. In nearly half of these studies, the LS was within normal limits whereas VS yielded a diagnosis of an esophageal motility disorder which may be of clinical significance to the patient’s management. The addition of VS to HR-EMS protocol may increase diagnostic yield in symptomatic patients.

Funding Agencies

None
A136 A RARE CAUSE OF AUTOIMMUNE ATROPHIC PANGASTRITIS COMPLICATED WITH GASTRIC OUTLET OBSTRUCTION
Authors: Akhtar D , Donaldson M A , Akhtar N H , Yang H , Donnellan F
Published: February 2022

Background

Chronic gastritis comes in two well recognized forms: environmental, which is most commonly antral or multifocal in distribution and is typically caused by Helicobacter Pylori (HP) infection, and autoimmune gastritis(AIG), which affects the corpus and fundus. Presented here is a case of autoimmune atrophic pangastritis(AIAP).

Aims

To increase awareness of a rare condition with limited data on available treatment modalities.

Methods

Case Report

Results

A 68-year old female with autoimmune hypothyroidism, presented with weight loss and elevated anti-TTG serology. Index esophagogastroduodenoscopy (EGD) biopsies demonstrated chronic non-specific gastritis limited to the antrum. Strict gluten free diet adherence was initiated. Testing for HLA revealed HLADq2 and HLADq8 negativity but HLADq2.5 positivity. Subsequent EGD showed a markedly atrophic appearing gastric body. The corresponding biopsies demonstrated persistent moderately chronic active gastritis with severe atrophy now involving the body, fundus and antrum. The biopsies were negative for HP. Notably, there was a lack of ECL-cell hyperplasia and the number of antral G cells appeared decreased. Anti-parietal cell antibody serology was positive with a titre of 1:80. Despite combination therapy with budesonide and mesalamine and treatment for HP given persistent symptoms, the patient’s course was further complicated by gastric-outlet obstruction (GOO). Urgent EGD biopsies showed pyloric stenosis requiring dilation. Endoscopic Ultrasound (EUS) guided biopsies were negative for malignancy. The patient was started on corticosteroids and azathioprine(AZA). Most recently, an EGD on AZA, continued to demonstrate severe chronic active pangastritis now with intestinal metaplasia involving the body. Corticosteroid therapy was reinitiated with a plan to start mycophenolate mofetil (MMF).

Conclusions

AIAP is a rarely described entity, not well documented in the literature. An eight patient case series reported a distinctive form of atrophic gastritis that was independent of HP infection with the absence of neuroendocrine hyperplasia that involved the body and antrum. Thyroid disease, specifically Hashimoto thyroiditis is present in about 40% of patients with AIG. Additionally, AIG progression to atrophic gastritis with intestinal metaplasia confers an increased risk for gastric adenocarcinoma in more than 10% of patients.

Limited literature exists regarding the management of AIAP. Pediatric data suggests the use of prednisone and/or azathioprine for AIAP. Furthermore, a recent case report of AIAP demonstrated clinical and endoscopic remission with MMF. Currently, no guidelines exist for the treatment, screening and monitoring of patients with AIAP. This case report presents a rare case of AIAP refractory to AZA complicated with GOO and adds to the little literature that exists.

Funding Agencies

None
A137 AN ELUSIVE GASTROINTESTINAL BLEED: A CASE OF RUPTURED CYSTIC ARTERY PSEUDOANEURYSM WITH PREVIOUS BILLROTH-II SURGERY
Authors: Jiang S X , Murray T , Leung V T , Ou G
Published: February 2022

Background

Cystic artery pseudoaneurysm (CAP) is a rare but potentially life-threatening cause of upper gastrointestinal (GI) bleeding and requires urgent intervention.

Aims

To describe the clinical enigma of CAP in the context of distorted anatomy and discuss management.

Methods

Case report and review of literature

Results

Case Report

A healthy 91-year-old man with a remote history of gastric ulcer perforation leading to Billroth-II surgery 40 years ago presented to a community hospital with melena. He had no abdominal pain and liver enzymes were normal. His hemoglobin was 97 g/L (from 137 g/L the month prior) with a BUN:Cr ratio of 50.6 mg/dL and white cell count of 14.4 x109/L. Upper endoscopy identified a large adherent clot in the stomach that could not be dislodged and was suspected to obscure the culprit lesion. Afferent and efferent limbs from previous Billroth-II surgery were identified but not intubated. He was managed supportively with acid suppression and blood transfusion, but his hemoglobin continued decreasing, leading to transfer to a tertiary centre. Upon arrival he had new-onset abdominal pain, rigors, and diaphoresis with a heart rate of 175 beats/minute and blood pressure of 75/40 mmHg. After resuscitation, emergent CT angiogram demonstrated acute contrast extravasation into the gallbladder in keeping with a ruptured CAP. He underwent successful coiling of the cystic artery. Following this, his abdominal pain resolved, and hemoglobin stabilized. Repeat endoscopy demonstrated Billroth-II anatomy without bleeding lesion. He was treated with antibiotics for presumed cholecystitis and discharged home for outpatient cholecystectomy.

Literature Review

CAP is a rare cause of hemobilia, described only in case reports. The complete hemobilia triad of jaundice, right upper quadrant pain, and GI bleeding is absent in the majority of cases, requiring endoscopic evaluation of the ampulla of Vater or contrast CT. The most common causes of CAP are iatrogenic from cholecystectomy, cholecystitis, gallstones, and malignancy. These mechanisms, whether through trauma or inflammation, lead to damage of the gallbladder wall and the cystic artery. Contained CAP can lead to intermittent bleeding whereas ruptured CAP causes brisk arterial bleeding, necessitating arterial embolization or emergent cholecystectomy. In cases of biliary obstruction, either from the original process or subsequent blood clot at the ampulla, ERCP can lead to successful decompression.

Conclusions

We present a case of ruptured CAP which eluded diagnosis due to diagnostic rarity, lack of clinical clues, and distorted anatomy. CAP should be considered with a history of recent cholecystectomy, acute cholecystitis, or gallstones. Maintaining an index of suspicion for rare causes of GI bleeding can ensure timely diagnosis and escalation to the appropriate level of care.

Funding Agencies

None
A166 CANNABIS USE IN CANADIAN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE FOLLOWING LEGALIZATION OF CANNABIS
Authors: Iablokov V , Gregor J C , Chande N , Jairath V , Khanna R , Asfaha S
Published: February 2022

Background

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are characterized by remitting and relapsing symptoms of abdominal pain, diarrhea, nausea, fatigue, and poor sleep. Most patients with IBD require chronic immunosuppressive therapy to maintain their disease in remission. Due to their disease chronicity, individuals often seek additional complementary or alternative medicines such as cannabis to treat their symptoms. Reports from the US show cannabis use in 12% of UC and 16% of CD patients. However, these numbers are likely underestimates given that cannabis remains illegal in many states.

Aims

The aim of our study is to evaluate the use of cannabis in a cohort of patients with IBD and to assess its association with IBD disease severity.

Methods

We conducted a prospective cohort survey of adult patients with IBD seen in tertiary care in London Health Sciences Centre. A 40-question online survey was completed by consenting patients and collected data on demographics, IBD disease history, cannabis use, and included the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) as a measure of disease severity. The study was approved by the Western University Ethics Committee. Statistical analyses was performed using a Chi squared test for categorical data, and a two-tailed t-test for continuous data.

Results

Completed surveys were obtained from 210 individuals (135 individuals with CD and 75 with UC) and demographics were similar between the CD and UC cohort. Fifty-six percent of participants reported cannabis use at least once in their lifetime, with 38% of participants reporting cannabis use in the preceding 6 months. Interestingly, 46 percent of life-time cannabis users did not divulge their cannabis use to their physicians. In patients with UC, those who actively used cannabis were less likely to be on 5-ASA therapy (9 active users vs 22 non-users, p<0.05). Medical therapy was otherwise similar between cannabis users and non-users. Surgical rates were similar between cannabis users and non-users amongst both IBD subtypes. With respect to the burden of disease, patients with CD reported higher rates of abdominal pain if they were active users, however, overall SIBDQ scores were not altered by cannabis use (21 user vs 20 non-user). Similarly, SIBDQ scores were similar amongst patients with UC who were cannabis users and non-users (20 user vs 16 non-user).

Conclusions

Cannabis use in patients with IBD is very common and much higher than previously reported prior to the legalization in Canada, but its use is not associated with lower disease severity based on patient reported outcomes. Our study also reveals that patients often do not report this use to their doctors so physicians must be aware of its prevalence amongst their IBD patient population.

Funding Agencies

None
A174 PERCEPTIONS OF CANNABIS USE IN WOMEN WITH INFLAMMATORY BOWEL DISEASE OF REPRODUCTIVE AGE: A CROSS-SECTIONAL STUDY
Authors: Tandon P , O’Connor K , Steinhart H , Deshpande A , Maxwell C , Huang V
Published: February 2022

Background

Cannabis use in inflammatory bowel disease (IBD) may lead to improvement in pain and general health perception. However, its use during pregnancy may result in adverse outcomes such as preterm birth and altered fetal brain development. It remains unknown how women with IBD perceive Cannabis use during pregnancy and whether they discuss its use with their health-care providers.

Aims

To determine practices in, and perceptions of, cannabis use during pregnancy in women with IBD of reproductive age.

Methods

Women with IBD (age 18–45) were recruited at Mount Sinai Hospital and via social media platforms. Participants anonymously completed surveys on baseline demographics and IBD characteristics. They also completed a Cannabis questionnaire which asked about current use, perceived risks during pregnancy, and discussions with health-care providers. Categorical variables were reported as frequencies and compared using the chi-square test. Continuous variables were reported as medians and compared using the Mann-Whitney U test.

Results

Sixty-four women were included, 26 (40.6%) with ulcerative colitis, 37 (57.8%) with Crohn’s disease, and 1 (1.6%) with indeterminate colitis. Nineteen (29.7%) were preconception, 40 (62.5%) were pregnant, and 5 (7.8%) were post-partum. Eleven (18.0%) patients reported current Cannabis use, 4 (6.3%) during pregnancy. Cannabis users were more likely to have discussed its use with a health-care provider compared to non-users (45.5% vs. 5.7%, p<0.001) and had longer IBD duration (12.00 vs. 9.00 years, p=0.05). Twenty-five (42.4%) were unsure of the risks of Cannabis use in pregnancy, of which only two had discussed this with a health-care provider. Reasons for fear of Cannabis use included risk of fetal oxygen restriction (n=13, 20.3%), impact on brain development (n=29, 46.0%), and risk of fetal respiratory issues (n=18, 28.6%). Only eight (12.5%) patients reported having a conversation about Cannabis use during pregnancy with their health-care provider; all of whom felt its consumption was unsafe during pregnancy.

Conclusions

Many women with IBD report being unsure of risks of Cannabis use during pregnancy. With the legalization of Cannabis in Canada, it is imperative patients and health-care providers discuss the risks and benefits of its use, particularly during vulnerable times such as pregnancy.

Funding Agencies

None
A177 INADEQUATE OR EXCESSIVE GESTATIONAL WEIGHT GAIN IN INFLAMMATORY BOWEL DISEASE AND IMPACT ON PREGNANCY AND NEONATAL OUTCOMES
Authors: Nguyen D M , Tandon P , Govardhanam V , Hanna Y , Tao J J , Cepo J , Maxwell C , Huang V
Published: February 2022

Background

Patients with inflammatory bowel disease (IBD) are at a risk of adverse pregnancy outcomes. Prior studies have suggested that inadequate gestational weight gain is associated with preterm birth and intrauterine growth restriction.

Aims

We sought to characterize the proportion of people with IBD who gain inadequate or excessive weight during pregnancy and how this affects pregnancy and neonatal outcomes.

Methods

Pregnant patients with ulcerative colitis (UC), Crohn’s disease (CD), and inflammatory bowel disease unclassified (IBD-U) were identified retrospectively at Mount Sinai Hospital from 2016 to 2020. Total gestational weight gain (GWG) was calculated as the difference of the weight recorded at time of labor and pre-pregnancy weight. GWG was categorized as inadequate GWG, adequate GWG, and excessive GWG based on the pre-pregnancy body-mass index and standards set by the U.S. Institute of Medicine. Neonatal-related outcomes were also recorded for each patient and included preterm delivery, small for gestational age (SGA) and large for gestational age (LGA). Multiple logistic regression was used to assess the association between gestational weight gain and outcomes while controlling for maternal age, history of gestational diabetes, and preconception disease activity.

Results

225 pregnancies were included (106 UC, 115 CD, 4 IBD-U). Forty-eight patients (21.3%) had inadequate, 91 (40.4%) adequate, and 86 (38.2%) excessive GWG. People of East Asian, African, and Hispanic ethnicity were more likely to have inadequate GWG. People with inadequate GWG were more likely than those with excessive GWG to have lower preconception BMI (21.7 vs 25.5 kg/m2, P=0.001). IBD type was not associated with inadequate GWG or excessive GWG, though people with inadequate GWG were 2-fold less likely to be on anti-TNF therapy. People with excessive GWG were more likely than those with adequate GWG to have babies with higher birth weight (3,364g vs 3,132g, P=0.003). People with inadequate GWG were not at increased risk of SGA compared to those with adequate GWG (adjusted odds ratio (aOR), 1.01; 95% CI: 0.37 – 2.71, P=0.99). Those with excessive GWG were substantially less likely to have an infant with SGA (aOR, 0.23; 95% CI: 0.07 – 0.72, P=0.01). On multivariable logistic regression analysis, excessive GWG was not associated with increased odds of delivering infants with LGA (aOR, 1.46; 95% CI: 0.54 – 3.95, P=0.46). There was no association between non-adequate gestational weight gain and preterm delivery or Caesarean delivery.

Conclusions

Less than half of persons with IBD have adequate GWG during pregnancy. Inadequate GWG was not associated with poor neonatal outcomes, and excessive GWG appeared to protect against delivering infants born SGA.

Funding Agencies

None
A178 BIOLOGIC THERAPY DURING PREGNANCY AS PER GUIDELINE RECOMMENDATIONS REDUCES ADVERSE PREGNANCY RELATED OUTCOMES
Authors: Tao J J , Govardhanam V , Tandon P , Huang V
Published: February 2022

Background

Inflammatory bowel disease (IBD) disease activity during pregnancy is associated with adverse neonatal and pregnancy-related outcomes. Biologics are used to suppress disease activity but crosses the placenta in the third trimester. Conflicting studies and guidelines on the timing of biologic dosing in pregnancy persist as we try to balance the risk of disease flare and possible adverse drug effects. The American Gastroenterology Association (AGA) recommends timing the final dose according to the half-life and dosing regimen of each biologic agent.

Aims

To compare neonatal and pregnancy-related outcomes in early versus late dosing of biologics.

Methods

This was a single-center retrospective cohort study conducted at Mount Sinai Hospital from 2016–2021. We included patients with an established diagnosis of IBD before pregnancy who were at least 18 years of age at the time of conception. All patients must have been treated with an IBD-specific biologic agent and had a documented final dose during the pregnancy. The early group received their last biologic dose earlier than the AGA recommendations and the late group received it within the recommended interval. A patient was considered to have a flare based on the overall clinical impression of their gastroenterologist informed by reported symptoms, investigations (fecal calprotectin, endoscopy), and response to treatment. Neonatal and pregnancy-related outcomes were compared amongst the two groups using the student’s t-test (for continuous variables) and Fischer’s exact test (for categorical variables) using SPSS Version 27.

Results

Of 322 patients who had a completed pregnancy at Mount Sinai Hospital, 107 were included in this study. 67 (62.6%) were in the early and 40 (37.4%) were in the late groups. Baseline characteristics including age, comorbidities, IBD phenotype and disease activity were similar between the two groups. The late group had significantly later gestational ages (37.4 vs 38.7 weeks, p=0.006), higher 5-minute Apgar scores (8.7 vs. 9.0, p=0.042), fewer NICU admissions (25.4% vs 5.0%, p=0.036), and fewer IBD flares (28.3% vs 11.1%, p=0.039) in the 6-month post-partum period. There were no significant differences in the rates of premature birth, caesarian sections, infections, and congenital abnormalities. Results are displayed in figure 1.

Conclusions

Our study suggests that late dosing of biologics according to the AGA guidelines was associated with favourable outcomes. However, this is an unadjusted analysis based on retrospective data and findings should be confirmed in a prospective manner to account for confounders.

Funding Agencies

None
A179 AUTOLOGOUS BONE MARROW TRANSPLANT FOR REFRACTORY CROHN’S DISEASE: A CASE SERIES
Authors: Buttar J , Akhtar N H , Akhtar D , Barker C , Bressler B , Atkinson K
Published: February 2022

Background

Crohn’s disease (CD), a form of inflammatory bowel disease (IBD) is a chronic, immune mediated condition characterized by gastrointestinal inflammation. Approximately 25% of CD patients have pharmacologically refractory disease, in which stem cell therapy has been shown to play a role.

Aims

A case series was performed to analyze the efficacy of autologous bone marrow transplantation (ABMT) for refractory CD in British Columbia(B.C).

Methods

A chart review was conducted on patients who had undergone ABMT for treatment refractory CD between 2001 to 2021 in B.C. Demographic, clinical, laboratory and endoscopic data was collected.

Results

Case details are summarized in Table 1. 3 patients(2 female and one male) were included. All patients failed conventional therapies prior to ABMT. 2 patients underwent surgical intervention (colectomy with ileostomy) prior to ABMT. Average time from diagnosis to ABMT was 8.83 + 6.6 years. All 3 patients received standard myeloablative therapy. There were no intestinal complications post ABMT. 6 months post-ABMT transplant, all 3 patients showed significant improvement, with CDAI scores <150. Endoscopic assessment post-ABMT revealed endoscopic remission in 2 of the 3 patients. 2 of the 3 patients were in clinical remission at 12 months follow up. 1 patient relapsed and required further immunosuppressive therapy. This patient was trialed on thalidomide at 15 months post-ABMT and ultimately passed away 18 months post-ABMT from an unrelated cause. 10 years post-transplant, the remaining 2 patients remain in clinical and endoscopic remission with CDAI scores <150.

Conclusions

Despite medical and surgical therapeutic advances, a subset of CD patients develop refractive disease associated with significant morbidity and mortality. In this population, there is increasing evidence in support of stem cell therapy as a treatment modality, with acute mortality less than 5% for patients with malignancy driven primarily by infectious complications and treatment-related toxicity. Clinical trials are currently underway to evaluate ABMT in CD. This case series presents the only Canadian data to date on the use of ABMT for refractory CDs and their subsequent follow up.

Funding Agencies

None
A184 REPURPOSING DRUGS FOR SPLEEN TYROSINE KINASE (SYK) PEDIATRIC PATIENTS USING HIGH-THROUGHPUT SCREENING
Authors: Chau S , Jardine S , Guo C , Warner N , Muise A
Published: February 2022

Background

Spleen Tyrosine Kinase (SYK) is a cytosolic, non-receptor tyrosine kinase with an imperative role in immune and non-immune processes. Recently, we identified six gain-of-function SYK variants in patients that presented multi-organ inflammation and immune dysregulation. The SYK variants displayed constitutive SYK phosphorylation in human embryonic kidney (HEK) 293T, colonic epithelial cells (SW480), and in knock-in heterozygous SYK mice. These observations mark SYK as a therapeutic target for autoimmune diseases.

Phenotype drug discovery accelerates this process and can be done successfully with an appropriate phenotype. A possible phenotype displayed by SYK variants is SYK phosphorylation, as high-throughput screening can identify hit compounds that reduce the constitutive activation of phosphorylated SYK (p-SYK).

Aims

Aim 1: Determine the screening phenotype with wildtype (WT) and SYK S550Y variant in HEK293T cells. Recently, we observed increased phosphorylation in gain-of-function SYK variants We hypothesize that we can use phosphorylated-SYK (p-SYK) levels to identify hit compounds that can decrease the kinase activity in these variants. With stable transfected SYK WT and SYK S550Y HEK293T cell-line, protein analyses will be completed to characterize the appropriate screening phenotype.

Aim 2

Establish an assay for high-throughput drug screening. We will utilize homogenous time-resolved fluorescence (HTRF) assay. The signal measured from HTRF is positively proportional to the level of p-SYK; therefore, we expect that S550Y cells will have a higher signal than the WT.

Aim 3

Validate hit compounds in HEK293T and zebrafish. We will create a dose-response curve with the hit compounds in in vitro and in vivo models.

Methods

We will use stable transfection to established overexpressing SYK WT and S550Y HEK293T cells. We will apply homogenous time-resolved fluorescence (HTRF) to quantify p-SYK levels during the drug screening.

Results

Protein analyses have verified high expression of p-SYK in stable transfected HEK293T cells. No stimulation was required, as the cells showed an increased phosphorylation level at baseline. Downstream signaling partners such as p-ERK and p-JNK of the MAPK pathway displayed an upregulation. This suggests that the sustained activation of p-SYK may consequently affect cellular processes and contribute to the clinical manifestations observed in patients.

Conclusions

This research study will identify hit compounds that can produce a safe and effective biological response in pediatric patients with gain-of-function SYK variants. Personalizing medicine throughout high-throughput drug screening can accelerate drug repurposing for pediatric patients with multiple systemic diseases and immune dysregulation.

Funding Agencies

None